Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Alert Curbs Enthusiasm For Hydroxychloroquine And Chloroquine

COVID-19 Treatment Should Be Limited To Clinical Trial Or Hospital Settings

Executive Summary

A drug safety communication published by the US FDA over hydroxychloroquine and chloroquine has cooled hopes that the drugs could be used as key treatments to address the coronavirus pandemic.

You may also be interested in...



FDA Guides On COVID-19 Obstacles To ANDA Studies

Specific guidance for ANDA sponsors on bioequivalence studies during the COVID-19 pandemic has been published by the US FDA.

Sandoz, Mylan And Teva Take Bigger Steps To Tackle COVID-19

Sandoz is sponsoring a major hydroxychloroquine trial while other major industry players like Teva, Mylan, Apotex, Stada and Lupin are also accelerating efforts to fight the coronavirus crisis. Accord and Wavelength Pharma have stepped up their manufacturing to meet demand, as the AAM has cancelled its annual meeting.

Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

Topics

Latest News
UsernamePublicRestriction

Register

GB149842

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel